Comprehensive DNA methylation study identifies novel progression-related and prognostic markers for cutaneous melanoma.

ABSTRACT:

Background

Cutaneous melanoma is the deadliest skin cancer, with an increasing incidence and mortality rate. Currently, staging of patients with primary melanoma is performed using histological biomarkers such as tumor thickness and ulceration. As disruption of the epigenomic landscape is recognized as a widespread feature inherent in tumor development and progression, we aimed to identify novel biomarkers providing additional clinical information over current factors using unbiased genome-wide DNA methylation analyses.

Methods

We performed a comprehensive DNA methylation analysis during all progression stages of melanoma using Infinium HumanMethylation450 BeadChips on a discovery cohort of benign nevi (n = 14) and malignant melanoma from both primary (n = 33) and metastatic

SUBMITTER: Wouters J 

PROVIDER: S-EPMC5458482 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature